Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00549289 · ClinicalTrials.gov registry record · Phase 3
Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-006)
A Phase 3 study, sponsored by Sirion Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00549289: Completed Phase 3 study, sponsored by Sirion Therapeutics.
NCT00549289 is a Phase 3 study that has completed, run by Sirion Therapeutics. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00549289, a Phase 3 study, has completed, sponsored by Sirion Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
The purpose of this phase III, open-label study is to determine the safety and tolerability of cyclosporine in the treatment of dry eye syndrome.
Interventions
- DRUG cyclosporine A
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 3 |
What the finished NCT00549289 record still lists
NCT00549289 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which cyclosporine A is the first listed.
NCT00549289 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00549289 about?
NCT00549289 is a clinical study titled "Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-006)". The purpose of this phase III, open-label study is to determine the safety and tolerability of cyclosporine in the treatment of dry eye syndrome.
What is the current status of trial NCT00549289?
This trial is currently completed. It is a Phase 3 study.
What interventions are being tested in trial NCT00549289?
The interventions under investigation include: cyclosporine A (DRUG).
Who is sponsoring clinical trial NCT00549289?
This trial is sponsored by Sirion Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.